- Home
- MYGN
MYGN
Myriad Genetics Inc.
as 11-15-2024 4:00pm EST
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 2.0B | IPO Year: | 1995 |
| Target Price: | $27.64 | AVG Volume (30 days): | 990.7K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.18 - $29.30 | Next Earning Date: | 11-07-2024 |
| Revenue: | $823,600,000 | Revenue Growth: | 12.15% |
| Revenue Growth (this year): | 13.85% | Revenue Growth (next year): | 7.73% |
Stock Insider Trading Activity of Myriad Genetics Inc. (MYGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DIAZ PAUL J | MYGN | President and CEO | Oct 11 '24 | Sell | $22.93 | 15,000 | $343,950.00 | 962,378 | |
| Muzzey Dale | MYGN | Chief Scientific Officer | Sep 11 '24 | Sell | $26.17 | 2,100 | $54,961.20 | 108,013 | |
| DIAZ PAUL J | MYGN | President and CEO | Sep 11 '24 | Sell | $26.72 | 15,000 | $400,800.00 | 962,378 | |
| Dreismann Heinrich | MYGN | Director | Sep 9 '24 | Sell | $27.05 | 10,000 | $270,520.00 | 121,648 | |
| Reitan Colleen F | MYGN | Director | Sep 3 '24 | Sell | $27.95 | 46,012 | $1,285,851.35 | 42,533 | |
| Ancona Margaret | MYGN | SVP, Chief of Staff | Aug 21 '24 | Sell | $27.82 | 11,538 | $320,987.16 | 79,366 | |
| Kumar Rashmi | MYGN | Director | Aug 19 '24 | Sell | $28.01 | 7,500 | $210,075.00 | 77,392 |
Latest Myriad Genetics Inc. News
MYGN Breaking Stock News: Dive into MYGN Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores
MT Newswires
3 days ago
Myriad Genetics Says Fetal Gender Test Available at Over 8,000 Stores in US
GlobeNewswire
3 days ago
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
Argus Research
4 days ago
MYGN: Lowering target price to $13.00
Simply Wall St.
7 days ago
Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Zacks
8 days ago
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View
GuruFocus.com
9 days ago
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ...
Zacks
9 days ago
Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics
Compare MYGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MYGN Myriad Genetics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.